Skip to main content
OpenTrials
Completed

NCT Number: NCT07058051

Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China

The purpose of this study is to evaluate the patterns of treatment, healthcare resources utilized and the burdens associated with non-segmental vitiligo (NSV) amongst participants in China

This study is a cross-sectional, multicenter, observational study of vitiligo patients in China. The cross-sectional design is sufficient to characterize the overall current burden of NSV.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Dermatology Hospital of Southern Medical University /ID# 276921, Guangzhou, Guangdong, China

Loading trial locations.

About this study

Cross-Sectional

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients, age ≥ 12.
  • Chinese patients meet the diagnosis of Non-Segmental Vitiligo (NSV) and 5≤ Total Vitiligo Area Scoring Index (T-VASI<50) with or without facial involvement.
  • Medical history available within the last 6 months.
  • Ability to understand the questionnaires, with parental support as required for adolescents (between ≥ 12 and < 18 years of age at inclusion visit).
  • Willing to provide a patient authorization form to use and disclose personal health information (or informed consent, where applicable) to participate in the study; for adolescent subjects, authorization and/or consent will be provided by a parent or legal guardian, where applicable.

Exclusion criteria

  • Unable or unwilling to comply with study requirements and electronic Patient-Reported Outcome (ePRO) collection.
  • Segmental or localized vitiligo.
  • Greater than 33% leukotrichia in areas of vitiligo on the face or on the body.
  • History of active skin disease other than vitiligo that could interfere with the assessment of vitiligo.
  • Patients who are participating in interventional clinical trial(s) at time of study visit.
  • Patients who are currently receiving treatment with any investigational drug/device/intervention or have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) prior to enrollment.

Treatment and study plan

Primary outcomes

  1. Total Vitiligo Area Scoring Index (T-VASI)

    Time frame: At Inclusion Visit (Day 1)

    The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100, with higher scores indicating more severe disease.

  2. Vitiligo Quality of Life Scale (VitiQoL)

    Time frame: At Inclusion Visit (Day 1)

    The VitiQoL is an 16-item instrument assessing impact of vitiligo on quality of life. 15 items are scored on a 7-point Likert scale, ranging from "not at all" to "all the time". An additional item (not contributing to total score) assesses current severity of condition on a 7-point scale ranging from "no skin involvement" to "most severe case"

Sponsors and collaborators

Lead sponsor

AbbVie

Industry

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jul 10, 2025
Registry last updated
Nov 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.